The stock of Prothena Corporation PLC (NASDAQ:PRTA) is a huge mover today! About 203,881 shares traded hands. Prothena Corporation PLC (NASDAQ:PRTA) has declined 7.81% since April 4, 2016 and is downtrending. It has underperformed by 8.90% the S&P500.
The move comes after 7 months positive chart setup for the $1.50B company. It was reported on Nov, 4 by Barchart.com. We have $59.51 PT which if reached, will make NASDAQ:PRTA worth $555.00 million more.
Analysts await Prothena Corporation PLC (NASDAQ:PRTA) to report earnings on November, 7. They expect $-1.23 EPS, down 68.49% or $0.50 from last year’s $-0.73 per share. After $-1.18 actual EPS reported by Prothena Corporation PLC for the previous quarter, Wall Street now forecasts 4.24% negative EPS growth.
Prothena Corporation PLC (NASDAQ:PRTA) Ratings Coverage
Out of 5 analysts covering Prothena Corp (NASDAQ:PRTA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prothena Corp has been the topic of 10 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Deutsche Bank initiated it with “Buy” rating and $73 target price in Thursday, November 3 report. The stock has “Outperform” rating given by Wedbush on Friday, February 19. The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned “Overweight” rating by Barclays Capital on Thursday, August 4. On Friday, May 13 the stock rating was initiated by Barclays Capital with “Overweight”. As per Thursday, January 21, the company rating was initiated by Credit Suisse. As per Tuesday, August 4, the company rating was maintained by Wedbush. The company was maintained on Thursday, November 19 by RBC Capital Markets.
According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in 2016 Q2. Its down 0.23, from 1.27 in 2016Q1. The ratio dived, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
Turner Invests Ltd Partnership has invested 0.86% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Moreover, Aqr Capital Mgmt Lc has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 17,277 shares. Ubs Oconnor Ltd Liability Corporation reported 28,380 shares or 0% of all its holdings. Amalgamated Financial Bank holds 0.01% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 3,670 shares. The Massachusetts-based Wellington Mngmt Group Incorporated Ltd Liability Partnership has invested 0.03% in Prothena Corporation PLC (NASDAQ:PRTA). Pinnacle Assoc holds 0.33% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 436,417 shares. Nuveen Asset Lc last reported 0.01% of its portfolio in the stock. Schwab Charles Inc has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Panagora Asset Mngmt has 959 shares for 0% of their US portfolio. Platinum Invest Mngmt Ltd owns 40,000 shares or 0.03% of their US portfolio. The New York-based Evercore Wealth Ltd Limited Liability Company has invested 0% in Prothena Corporation PLC (NASDAQ:PRTA). Pub Employees Retirement Association Of Colorado has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Royal Fincl Bank Of Canada has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Moreover, Palo Alto Limited Liability has 2.08% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 788,618 shares. Blackrock Institutional Com Na, a California-based fund reported 848,925 shares.
Insider Transactions: Since May 23, 2016, the stock had 0 insider purchases, and 7 insider sales for $3.29 million net activity. HOMAN ARTHUR W sold $488,813 worth of Prothena Corporation PLC (NASDAQ:PRTA) on Wednesday, July 20. 12,000 Prothena Corporation PLC (NASDAQ:PRTA) shares with value of $733,204 were sold by Walker Karin L. 5,000 shares were sold by Selkoe Dennis J., worth $273,076. Kinney Gene G. also sold $1.14 million worth of Prothena Corporation PLC (NASDAQ:PRTA) on Thursday, October 20.
More news for Prothena Corporation PLC (NASDAQ:PRTA) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on April 02, 2013. Fool.com‘s article titled: “Why Prothena Corporation Plc is Soaring Higher Today” and published on March 20, 2015 is yet another important article.
PRTA Company Profile
Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.